title: Case Report of an ABO-Incompatible Living-Donor Liver Transplant for a Familial Amyloid Polyneuropathy Patient.
abstract: Liver transplant is a treatment for familial amyloid polyneuropathy. Few cases of ABO-incompatible living-donor liver transplant for familial amyloid polyneuropathy exist. The outcome of an ABO-incompatible living-donor liver transplant has improved recently, using local infusion therapy and rituximab prophylaxis. Here, we describe a successful ABO-incompatible living-donor liver transplant in a patient with familial amyloid polyneuropathy in whom disease progression ceased at 2 years' follow-up. Additionally, no evidence of acute or chronic rejection, or adverse events of the immunosuppressive therapy, was seen. As a postoperative complication, fatty changes in the grafted liver because of malnutrition or adverse events of corticosteroids were confirmed by a liver biopsy taken early after transplant. The main cause of malnutrition was considered to be gastrointestinal dysfunction caused by familial amyloid polyneuropathy. Therefore, before deterioration of digestive function, liver transplants should be considered for familial amyloid polyneuropathy. This case suggests that an ABO-incompatible living-donor liver transplant may provide greater opportunities for familial amyloid polyneuropathy patients.
authors.affiliation: From the Department of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nakanuma
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takamura
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Shoji
authors.forename: Hironori
authors.initials: H
authors.lastname: Hayashi
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Tajima
authors.forename: Hisatoshi
authors.initials: H
authors.lastname: Nakagawara
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Miyashita
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Tani
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ohta
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D028227:Amyloid Neuropathies, Familial / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000601:surgery*; D001706:Biopsy; D001787:Blood Group Incompatibility / Q000276:immunology*; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival; D006648:Histocompatibility; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016031:Liver Transplantation / Q000379:methods*; D019520:Living Donors; D008297:Male; D010951:Plasma Exchange; D000069283:Rituximab / Q000008:administration & dosage; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000017:ABO Blood-Group System; D007166:Immunosuppressive Agents; D000069283:Rituximab